Glucose Fresenius

Glucose Fresenius is a sterile intravenous solution for injection that contains glucose monohydrate as its active ingredient. Manufactured for the European market, this excipient‑type product provides a readily available source of carbohydrate in a liquid form. It is supplied as a clear, isotonic solution intended for infusion or bolus administration in clinical settings where rapid glucose delivery is required to patients undergoing surgery or critical care.

Glucose Fresenius is used in clinical practice primarily as an intravenous carbohydrate source and solvent for drug dilution.

- To provide rapid energy to patients with hypoglycemia or during peri‑operative fasting. - As a carrier solution for the reconstitution of lyophilized medications administered intravenously. - For maintenance of fluid and electrolyte balance in patients requiring parenteral nutrition. - To correct or prevent low blood glucose levels during critical care or trauma resuscitation. - As an osmotic agent in certain diagnostic or therapeutic infusion protocols.

Adverse reactions to Glucose Fresenius are generally infrequent, but they can be categorized by frequency and severity.

Common: - Mild local irritation or erythema at the infusion site. - Transient hyperglycemia, especially with rapid or large-volume administration. - Nausea or a feeling of warmth during infusion. - Headache or dizziness related to rapid changes in blood glucose. - Transient increase in serum osmolality causing mild thirst.

Serious: - Severe hyperglycemia leading to osmotic diuresis or electrolyte disturbances. - Hypersensitivity reactions such as urticaria, bronchospasm, or anaphylaxis. - Volume overload or pulmonary edema in patients with compromised cardiac function. - Acute renal impairment due to osmotic nephrosis in susceptible individuals. - Metabolic acidosis secondary to excessive glucose metabolism in rare cases.

When using Glucose Fresenius, clinicians should observe several precautionary measures to minimize risks and ensure appropriate patient selection.

- Assess baseline blood glucose and monitor levels frequently during and after infusion. - Adjust infusion rate in patients with diabetes, renal insufficiency, or heart failure to avoid hyperglycemia or fluid overload. - Use aseptic technique to prevent contamination of the sterile solution. - Verify compatibility with co‑administered drugs, as high glucose concentrations may affect stability. - Avoid rapid large-volume boluses unless clinically indicated. - Consider electrolyte status, particularly sodium and potassium, before administration. - Document infusion parameters and patient response in the medical record.

Glucose Fresenius may interact with certain medications or clinical conditions, requiring careful consideration of compatibility and patient status.

Avoid: - Co‑administration with insulin or other hypoglycemic agents without adjusting doses, to prevent severe hypoglycemia. - Simultaneous infusion of high‑concentration dextrose solutions with calcium‑containing medications, which can precipitate calcium phosphate.

Use with caution: - Concurrent use of diuretics or antihypertensives in patients at risk of fluid overload. - Administration in patients receiving sodium‑containing fluids, to avoid hypernatremia. - Use in individuals on beta‑blockers, as altered glucose metabolism may mask hypoglycemia symptoms.